Original ReportA Randomized, Placebo-Controlled Phase 3 Trial (Study SB-767905/013) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With Non-Cancer Pain
Under an Elsevier user license
open archive
Key words
Alvimopan
peripherally acting mu-opioid receptor (PAM-OR) antagonist
pain
opioid analgesics
constipation
Cited by (0)
This study (SB-767905/013) was funded by GlaxoSmithKline (GSK). Funding for medical editorial assistance for this manuscript was provided by Adolor Corporation, Exton, Pennsylvania, and GSK, Philadelphia, Pennsylvania.
Copyright © 2011 American Pain Society. Published by Elsevier Inc. All rights reserved.